Weight loss drug use now has a much-needed protocol, Pg14

Key Highlights:

• The World Health Organization (WHO) has released its first guidelines on using weight-loss drugs like semaglutide and tirzepatide for treating obesity.
• The guidelines suggest these therapies can be used for long-term obesity treatment (six months or more) in all adults, except pregnant women, alongside intensive behavioral therapy.
• GLP-1 therapies production can only cover approximately 10% of the global obese population due to production limitations.
• Priority for medication should be given to adults with a BMI over 35, or over 30 with severe obesity-related conditions.

Detailed Insights:

• The WHO now recognizes obesity as a chronic medical condition needing treatment to reduce risks of diseases like diabetes and heart disease.
• The guidelines emphasize treating obesity as a lifelong condition requiring holistic care, including therapies, surgeries, and lifestyle changes.
• Challenges to drug access include limited production capacity, high costs, and lack of insurance coverage for GLP-1 therapies in many countries, including India.
• For India, integrating obesity screening and management into the Ayushman Bharat Health and Wellness Centres is suggested for a chronic care model.
• Securing procurement and regulatory systems is crucial in India to prevent falsified GLP-1 products and ensure a safe, uninterrupted supply.

Key Concepts Involved:

• Semaglutide/Tirzepatide: Weight-loss drugs that are GLP-1 receptor agonists, mimicking a natural hormone to regulate appetite and blood sugar.
• GLP-1 (Glucagon-Like Peptide-1): A hormone that stimulates insulin release and reduces glucagon secretion, helping to lower blood sugar levels and promote weight loss.
• BMI (Body Mass Index): A measure of body fat based on height and weight, used to classify individuals as underweight, normal weight, overweight, or obese.